Navigation Links
Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
Date:4/4/2012

NEW YORK, APRIL 4, 2012 A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident. There are currently no FDA-approved treatments or prophylactics available to manage the condition, known as radiation gastrointestinal syndrome (RGS), which is associated with weight loss, vomiting, diarrhea, dehydration, systemic infection, and in extreme cases septic shock and death.

The research was conducted in mice by investigators at Memorial Sloan-Kettering Cancer Center and The University of Texas MD Anderson Cancer Center and will be published in the May 2012 issue of The Journal of Clinical Investigation.

The GI system is maintained through the continuous infusion of epithelial cells produced by specialized stem cells located in gland-like structures called crypts found in the epithelial lining of the small intestines and colon. High-dose irradiation kills these stem cells and destroys the protective epithelial barrier, or mucosa, resulting in onset of RGS within days of exposure.

According to the study, administration of a drug called 2A2 anti-ceramide antibody inhibited cell death (apoptosis) in blood vessels within the GI tract and improved 90-day survival from 0 percent to 80 percent among mice exposed to 15 Gy whole-body irradiation.

"We discovered that using this monoclonal antibody to inhibit blood vessel damage and dysfunction led to a dose-dependent increase in the number of surviving stem cells, which are highly active and responsible for repopulation of the damaged GI epithelium," said the study's corresponding author Richard N. Kolesnick, MD, a member of Memorial Sloan-Kettering's Molecular Pharmacology and Chemistry Program whose laboratory conducted the research experiments.

Developed by investigators at MD Anderson, the drug works by interfering with ceramide a lipid molecule that plays a role in apoptosis generated on the surface of the endothelial cells that make up the smallest blood vessels of a tumor.

The US Department of Health and Human Services has placed significant emphasis on the development and deployment of new therapies and countermeasures to protect first responders, military personnel, and others who are required to enter into areas of potential radiation contamination. Dr. Kolesnick and colleagues are working to develop anti-ceramide antibody as an agent used not only to protect against the damaging effects of radiation prior to exposure, but also to mitigate those effects after exposure.


'/>"/>

Contact: Esther Napolitano
napolite@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Related medicine news :

1. Antibody treatment protects monkeys from Hendra virus disease
2. Blood Antibody May Signal Start of Ovarian Cancer
3. Specialized regulatory T cell stifles antibody production centers
4. Antibody Finding Might Help in Search for HIV Vaccine
5. Disorderly enzyme is key for antibody diversity
6. Combination antibody therapy shows promise in metastatic melanoma
7. Antibody-guided drug works against acute lymphoblastic leukemia
8. Antibody production gets confused during long-term spaceflight
9. Tiny antibody fragments raised in camels find drug targets in human breast cancer cells
10. Tufts receives patent for antibody treatment against hemolytic uremic syndrome
11. HJF signs distribution agreement for antibody to evaluate prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, ... and organizations with the tools and information to lower the costs, and increase ... the cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
(Date:2/6/2016)... , ... February 06, 2016 ... ... 303-368-6225 , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE ... perioperative nurses in the world with an estimated 5000 perioperative nurses in ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is ... (YUCC) . This event brings together top non-profit leaders, ultimate organizations, and coaches from ... Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and Education, describes this ...
(Date:2/6/2016)... Viejo, CA (PRWEB) , ... February 06, 2016 , ... ... quickly and easily add warm color grades to their footage. A LUT is a ... every pixel's color to the corresponding color indicated by the table. By manipulating each ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Patients in Alabama ... focused ultrasound (HIFU) therapy no longer have to travel out ... its partnership with Urology Centers of Alabama to ... FDA-cleared procedure for qualifying patients. Alabama ... in the treatment of prostate cancer using many different modalities. ...
(Date:2/5/2016)... 5, 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ... CEO, will be presenting at Source Capital Group,s 2016 Disruptive ... at 2:15 p.m. ET on Wednesday, February 10, ... discussion taking place at 3:15 p.m. ET. http://www.aethlonmedical.com ... hour after the conclusion of the live event. The panel ...
(Date:2/5/2016)... 5, 2016 Dehaier Medical Systems Ltd. ... "Company"), which develops, markets and sells medical devices ... China and international markets, today announced ... to concentrate the Company,s resources to develop its ... and to focus more on its major businesses. ...
Breaking Medicine Technology: